Case Studies
1,226 selected projects

Case Studies

From pandemic-era vaccine trials to ATMP programs, logistics operations to bioequivalence projects — selected outcome-driven studies. Some cases are anonymized for confidentiality.

Sponsor profiles we work with

Global Big Pharma Emerging Biotech Turkish Pharma & Biotech Medical Device Manufacturers Public Health Institutes
1,226
Completed Projects
%95+
Employee Retention
6
Countries
3,500+
Peer-Reviewed Publications
Neurology Published

Chronic Inflammatory Demyelinating Polyneuropathy — Epidemiological Registry

134,448 patients · tertiary/quaternary healthcare centers

  • Omega’s largest patient enrollment study
  • Real-world data generation in a rare neurological disease population
  • Multi-center, longitudinal patient follow-up design
Contact us for details →
Cardiovascular Published

Essential Hypertension Prognostic Risk Observational Study

46,813 patients · 275 centers

  • Simultaneous data collection across 275 centers — large-scale field operations across Türkiye
  • Population-based risk stratification and prognostic modeling
Contact us for details →
Vaccines & Infectious Disease Published

CoronaVac Phase 3 — Inactivated SARS-CoV-2 Vaccine

10,214 participants · 25 centers · Phase 3

  • Vaccine efficacy 83.5% — published in The Lancet (2021)
  • Entire operation from design to IWRS randomization ran in-house at Omega
  • Underpinned the emergency use authorization (Jan 13, 2021)
Publication: The Lancet (2021) Vaccine details →
Cardiovascular Published

National Hypertension Prevalence Monitoring Study

31,837 volunteers · across Türkiye

  • A national study that systematically measured blood pressure prevalence across Türkiye
  • Generated data that directly informed public health policy
Contact us for details →
Other Published

Dialysis Registry — National Kidney Registry Study

25,000 patients · 390 centers

  • 390 centers — Omega’s broadest site network
  • Long-term longitudinal data on chronic kidney disease management
Contact us for details →
Vaccines & Infectious Disease Published

TURKOVAC Booster Dose — Phase 2 & AE Analysis

4,340 patients · 41 centers (booster) + 1,266 patients (AE)

  • Marked neutralizing antibody superiority against the Delta variant
  • Two peer-reviewed publications (2022, 2024) + first domestic vaccine EUA evidence (Dec 22, 2021)
Publication: Vaccines (2022) Vaccine details →
Respiratory Published

GSK BREATHE — MENA Regional COPD Prevalence Survey (Türkiye Arm)

General population aged ≥40 · 11 countries · 62,086 participants

  • For the GSK-supported survey run with a standardised methodology across 10 MENA countries plus Pakistan, Omega delivered the Türkiye arm — field operations, telephone interviews and medical translation
  • 62,086 participants; regional COPD prevalence 3.6% (Tageldin et al.) — design paper El Hasnaoui et al., Respir Med (2012)
  • Satellite publications with Turkish respiratory investigators (Uzaslan, Sayiner) on symptom distribution, disease burden and CAT validation
Contact us for details →
Immunology Published

GSK SNAPSHOT Program — Prevalence of Asthma, Allergic Rhinitis, Bipolar Disorder & BPH

9,959 participants (Türkiye) · 33,486 participants / 5 countries · cross-sectional epidemiological

  • Türkiye asthma prevalence 4.4% — BMC Pulmonary Medicine (2018); allergic rhinitis 6.4% — Allergy, Asthma & Clinical Immunology (2018)
  • The single program measuring asthma, allergic rhinitis, bipolar disorder and BPH together in one general-population sample
  • Omega scope (2014–2015): ethics committee submissions, field operations, phone visits, training and medical translation
Contact us for details →
Cardiovascular Published

Coronary Care Unit — Acute Myocardial Infarction Registry

1,945 patients · 53 centers

  • National-level assessment of acute MI management
  • Cross-center comparison of coronary care quality
Contact us for details →
Oncology Published

NSCLC Stage III — Radiosensitizer Phase 3

659 patients · 100 centers · Phase 3

  • Randomized controlled oncology trial across 100 centers — operational scale
  • Advanced-stage patient enrollment and follow-up in radiation oncology
Contact us for details →
Logistics & Depot Published

MoH Smoking Cessation Program Logistics

340,000 IMPs · 227 sites · 81 cities

  • The only organization to provide depot and distribution services for the project
  • Uninterrupted cold chain and delivery coordination across the country
Contact us for details →
Metabolism & Endocrine Published

Türkiye Metabolic Syndrome Epidemiological Study (MetSend)

7,500 volunteers · 15 centers · epidemiological

  • A landmark study determining metabolic syndrome prevalence across Türkiye
  • A national dataset that shaped cardiometabolic risk management
Contact us for details →
Respiratory Published

Tiotropium COPD Phase 3 — BIFIZ-2

6,000 patients · 500 centers · randomized Phase 3

  • 500 centers — end-to-end management of the Türkiye arm of an international multi-center Phase 3
  • Randomized, double-blind, placebo-controlled lung function cohort
Contact us for details →
Cardiovascular Published

Candesartan Pharmacovigilance — ATACAND-2 Phase 4

5,090 patients · 300 centers · Phase 4

  • Large-scale real-world safety data in essential hypertension
  • Comparative pharmacovigilance across monotherapy and combination therapy
Contact us for details →
Oncology Published

Breast Cancer Screening Program — METAR

5,000 participants · national screening program

  • A community-based breast cancer screening operation targeting early detection
  • Management of screening participation and access logistics
Contact us for details →
Immunology Published

EuroSpA — Biologic Therapy Registry in Inflammatory Rheumatic Disease

4,100 patients · 15 centers · international registry network

  • Integration of Türkiye data into the European EuroSpA research consortium
  • Monitoring of efficacy, safety and drug survival on biologic therapy
Contact us for details →
Cardiovascular Published

HITIP — Hyperlipidemia Treatment Patterns in Türkiye

4,226 patients · 362 centers · 1997

  • A wide-site-network indicative study dating from Omega’s early years
  • A national snapshot of lipid management in the pre-atorvastatin era
Contact us for details →
Immunology Published

Atopic Dermatitis Patient Journey Registry (PF-NIS-AD)

5,000 patients · observational dermatology

  • Türkiye’s comprehensive patient journey registry for diagnosed atopic dermatitis
  • Real-world clinical practice data from diagnosis to treatment
Contact us for details →
Metabolism & Endocrine Published

EASYDIA — Sulfonylurea Effectiveness in Type 2 Diabetes

3,123 patients · 225 centers · observational

  • Comparative real-world evidence across monotherapy and dual combination
  • A broad network spanning primary and secondary care clinics
Contact us for details →
Cardiovascular Published

SALTURK — Hypertension and Salt Intake in the Turkish Population

1,970 target participants · 14 centers · 24-hour urinary sodium

  • Omega ran the field operations for the Turkish Hypertension and Kidney Diseases Association study
  • Daily salt intake ≈18 g (24-h urinary sodium 308.3 mmol/day) — ~3.6× the WHO recommendation; salt intake positively correlated with blood pressure
  • Erdem et al., Blood Pressure (2010) — cited 250+ times
Contact us for details →
Cardiovascular Published

SALTURK II — Dietary Sources of High Sodium Intake in Türkiye

National cross-sectional · 24-hour urinary sodium · dietary source analysis

  • The SALTURK follow-up: daily salt intake 14.8 g/day — still ~3× the WHO recommendation
  • Quantified the dietary sources of high sodium intake (bread first) nationally — the evidence base for salt-reduction policies
  • Erdem et al., Nutrients (2017)
Contact us for details →
Other Published

CREDIT — Chronic Kidney Disease Prevalence in Türkiye

10,748 adults · 15-25 centers · prevalence + 4-year follow-up

  • With the Turkish Nephrology Association: CKD prevalence in Türkiye 15.7% (women 18.4% / men 12.8%)
  • A 4-year incidence follow-up layered on the prevalence cross-section — Türkiye’s national CKD data infrastructure
  • Süleymanlar et al., Nephrology (Carlton) (2010) — cited 600+ times
Contact us for details →
Other Published

Türkiye Erectile Dysfunction Prevalence Study — ED

4,200 men · 1997-98 · national epidemiological field study

  • One of the first national ED prevalence field studies, run in Omega’s founding years
  • Age-adjusted ED prevalence 69.2% (mild 33.2% · moderate 27.5% · severe 8.5%); prevalence and severity increase with age
  • Akkus et al., European Urology (2002) — cited 460+ times
Contact us for details →
Other Anonymized

BPH-Prev — Benign Prostatic Hyperplasia Prevalence in Türkiye

Epidemiological field study · urology · men aged 40+

  • One of the few studies measuring the national BPH/LUTS burden in adult men with field data
  • Field operations and data management with the urology clinical epidemiology group ran at Omega

Anonymized cards are presented without sponsor names or specific study data due to confidentiality obligations. Detailed references are available on request.

Let your project be the next case study

Contact Us